On January 12, 2021, AIkido Pharma Inc., a Delaware corporation (the “Company”), reconvened its 2020 annual meeting of stockholders (the “Meeting”). At the Meeting, the Company’s did not obtain the approval from stockholders that held a majority of the issued and outstanding shares of common stock as of the record date that was set for determination of stockholders entitled to notice and to vote at the Meeting of the proposal to amend the Company’s amended and restated certificate of incorporation (the “Amended and Restated Certificate of Incorporation”) to effect a reverse stock split of the Company’s common stock to a ratio of up to one-for-ten.
News 
Market Data 
Discover 
